Furthermore, bioinformatics analyses of different public datasets revealed that GBM patients with increased CDK1 expression had reduced survival time (Fig. 6H, I), confirming the importance of CDK1 in regulating GBM progression. This evidence concerns the gene CDK1 and glioblastoma.